Dihexa: The HGF/c-Met Peptide That Builds New Synapses — Mechanism, Evidence, and Safety Questions in 2026

Last updated: March 2026 | Medically reviewed content | Browse Research Peptides

In 2013, a team at Washington State University published a finding that sounded too good to be true: a small peptide derivative called Dihexa was 10 million times more potent than brain-derived neurotrophic factor (BDNF) at promoting new synaptic connections between neurons. The compound, designed as a stable analogue of angiotensin IV, could cross the blood-brain barrier after oral administration, reverse cognitive deficits in aged and dementia-model rats, and promote the formation of new dendritic spines — the tiny protrusions on neurons where synaptic connections form. If the preclinical data translated, it would represent one of the most potent cognitive-enhancing molecules ever characterized.

A decade later, Dihexa remains one of the most controversial and discussed compounds in nootropic and peptide research communities. It has never entered formal human clinical trials. Its mechanism of action, while increasingly well-characterized, raises as many questions as it answers. And its extraordinary potency cuts both ways — the same mechanisms that could restore cognitive function might also promote unwanted cell growth if dysregulated. This article examines what the science actually says about Dihexa in 2026: the mechanism, the preclinical evidence, the safety questions, and how it fits within the broader landscape of cognitive peptide research.

The Brain Renin-Angiotensin System: Why Blood Pressure Peptides Affect Cognition

Most people associate the renin-angiotensin system (RAS) with blood pressure regulation. Angiotensin II — the most studied RAS peptide — constricts blood vessels, promotes sodium retention, and stimulates aldosterone release. ACE inhibitors and angiotensin receptor blockers (ARBs), which block this system, are among the most prescribed medications worldwide for hypertension and heart failure.

What most clinicians and patients don’t realize is that the brain has its own local renin-angiotensin system, completely independent of the peripheral cardiovascular RAS. The brain RAS produces all the same components — angiotensinogen, renin, ACE, angiotensins I through IV — but uses them for fundamentally different purposes: learning, memory, neural plasticity, and cognitive function (Wright & Harding, 2011, Progress in Neurobiology).

Angiotensin IV: The Cognitive Peptide

Angiotensin IV (Ang IV) is a hexapeptide fragment (Val-Tyr-Ile-His-Pro-Phe) produced by sequential enzymatic cleavage of angiotensin II. Unlike its parent peptides, Ang IV has minimal cardiovascular effects. Instead, it acts primarily in the brain, where it binds to the AT4 receptor (later identified as insulin-regulated aminopeptidase, IRAP) and promotes:

• Memory consolidation: Ang IV enhances memory performance in passive avoidance, water maze, and object recognition tasks when administered intracerebroventricularly (ICV) in rodents
• Long-term potentiation (LTP): Ang IV facilitates LTP in the hippocampus — the electrophysiological correlate of memory formation
• Synaptic connectivity: Ang IV promotes dendritic spine formation and synaptogenesis
• Neuroprotection: Ang IV protects against ischemic and excitotoxic neuronal damage

The problem with Ang IV as a therapeutic: it has a plasma half-life of less than 1 minute (rapid degradation by aminopeptidases and endopeptidases) and cannot cross the blood-brain barrier when administered systemically. This makes it pharmacologically useless — you’d need continuous intracerebroventricular infusion to maintain brain levels, which is impractical for cognitive enhancement.

The Search for Stable Ang IV Analogues

Joseph Harding and John Wright at Washington State University spent over two decades developing metabolically stable analogues of Ang IV that could cross the blood-brain barrier and resist enzymatic degradation. Their approach involved systematic modification of the Ang IV peptide backbone — replacing natural L-amino acids with D-amino acids, substituting degradation-susceptible bonds, and modifying terminal groups to resist exopeptidases. This program produced several generations of increasingly stable and potent analogues, culminating in Dihexa (Benoist et al., 2012, Journal of Pharmacology and Experimental Therapeutics).

Discovery of Dihexa: From Angiotensin IV to a Cognitive Peptide

Dihexa (N-hexanoic-Tyr-Ile-(6) aminohexanoic amide) emerged from the Harding-Wright laboratory as the most potent and stable member of the Ang IV analogue series. Its formal chemical name describes its structure: a modified tripeptide core (Tyr-Ile) flanked by an N-terminal hexanoic acid group and a C-terminal 6-aminohexanoic acid amide, creating a molecule that retains the biological activity of the Ang IV binding pharmacophore while completely resisting enzymatic degradation.

Key Design Features

• Metabolic stability: The hexanoic acid cap on the N-terminus and aminohexanoic amide on the C-terminus prevent exopeptidase cleavage — the primary degradation mechanism for natural Ang IV
• BBB penetration: The lipophilic hexanoic groups significantly increase LogP (lipophilicity), enabling passive diffusion across the blood-brain barrier
• Oral bioavailability: Unlike most peptides, Dihexa demonstrated cognitive effects when administered orally in animal models, suggesting significant oral absorption and BBB transit
• Molecular weight: 487 Da — below the 500 Da Lipinski “rule of five” threshold for oral drug candidates

Patent and Development Status

The Washington State University research foundation holds patents on Dihexa and related analogues. A startup company (M3 Biotechnology, now Athira Pharma) was founded to develop next-generation compounds based on the Harding-Wright discoveries. However, Athira pivoted away from Dihexa specifically and developed a different lead compound (fosgonimeton/ATH-1017), which targets the same HGF/c-Met pathway but through a different mechanism. The Athira clinical program experienced significant setbacks in 2021-2023 (data integrity concerns, CEO departure), and fosgonimeton failed to meet primary endpoints in a Phase 2 Alzheimer’s trial in 2023.

Dihexa itself has never entered formal clinical development, remaining a research compound.

Mechanism of Action: HGF/c-Met and Synaptic Connectivity

The breakthrough in understanding Dihexa’s mechanism came in 2013, when McCoy et al. published the landmark study revealing that Dihexa and its parent compound Ang IV do not primarily act through the AT4/IRAP receptor as originally believed. Instead, they function as potentiators of the hepatocyte growth factor (HGF)/c-Met receptor signaling pathway — a mechanism with profound implications for both cognitive enhancement and safety (McCoy et al., 2013, Journal of Pharmacology and Experimental Therapeutics).

The HGF/c-Met Pathway in the Brain

Hepatocyte growth factor (HGF), despite its name, is a pleiotropic growth factor expressed throughout the brain. Its receptor, c-Met (a receptor tyrosine kinase), is highly expressed on hippocampal neurons, cortical neurons, and neural progenitor cells. HGF/c-Met signaling in the brain promotes:

• Synaptogenesis: HGF promotes the formation of new synapses by stimulating dendritic spine growth and presynaptic vesicle clustering
• Neuronal survival: c-Met activation triggers PI3K/AKT and Ras/ERK survival signaling cascades that protect neurons from apoptotic and excitotoxic death
• Neural progenitor proliferation: HGF promotes the proliferation of neural stem/progenitor cells in the subventricular zone and hippocampal dentate gyrus
• Neurite outgrowth: HGF stimulates axonal extension and dendritic branching through cytoskeletal reorganization
• Anti-inflammatory effects: HGF suppresses microglial activation and neuroinflammation through NF-?B inhibition

How Dihexa Potentiates HGF/c-Met

Dihexa does not directly activate c-Met. Instead, it acts as a potentiator — it enhances the signaling response when HGF binds to c-Met, amplifying a signal that is already present. The proposed mechanism involves Dihexa stabilizing the HGF/c-Met complex or promoting c-Met dimerization (the prerequisite for receptor activation), effectively lowering the threshold for HGF-induced signaling.

This potentiating mechanism explains several features of Dihexa’s pharmacology:

• Extraordinary potency: Because Dihexa amplifies existing HGF signaling rather than activating c-Met de novo, it is effective at picomolar concentrations — far below the nanomolar concentrations typically needed for direct receptor agonists
• Dependence on endogenous HGF: Dihexa’s effects require the presence of HGF. In the absence of HGF, Dihexa has no activity — it is a potentiator, not an agonist
• Specificity for neural connectivity: Because HGF/c-Met is naturally active during synaptogenesis and neural repair, Dihexa amplifies physiologically appropriate signals rather than creating artificial ones

The 10? Potency Factor

The widely cited “10 million times more potent than BDNF” claim comes from comparative assays measuring the ability of Dihexa vs BDNF to promote dendritic spine formation in hippocampal neuron cultures. At picomolar concentrations (10?¹² M), Dihexa produced equivalent spinogenesis to BDNF at nanomolar concentrations (10?? M relative activity). This represents a roughly 10? (10 million) fold difference in effective concentration for the specific endpoint of spine formation in vitro. This comparison is technically accurate but requires significant context, as discussed in the dedicated section below.

Preclinical Evidence: What the Animal Studies Show

Aged Rat Cognitive Studies

The strongest preclinical data for Dihexa comes from cognitive testing in aged rats — animals that model the natural cognitive decline of aging without genetic manipulation:

Morris Water Maze (spatial memory): Aged rats (24 months, equivalent to ~70 human years) treated with Dihexa (subcutaneous or oral) showed significantly improved spatial learning and memory compared to vehicle-treated aged controls. Performance approached — though did not reach — that of young adult rats. The improvement correlated with increased dendritic spine density in hippocampal CA1 neurons, measured by Golgi staining post-mortem (McCoy et al., 2013).

Scopolamine-induced amnesia: Dihexa reversed the memory-impairing effects of scopolamine (a muscarinic acetylcholine receptor antagonist used to model cholinergic cognitive deficits) in young rats, suggesting effects on memory consolidation that are independent of aging per se.

Duration of effect: Cognitive improvements persisted for several weeks after Dihexa treatment was discontinued, consistent with a structural mechanism (new synapse formation) rather than a purely pharmacological one (receptor occupancy). This persistence is one of Dihexa’s most distinctive features — most cognitive enhancers require ongoing administration.

Dendritic Spine Density

The most direct evidence for Dihexa’s synaptogenic activity comes from histological analyses of hippocampal neurons in treated vs untreated animals:

• Aged rats treated with Dihexa showed 35-50% increases in dendritic spine density in hippocampal CA1 pyramidal neurons compared to aged controls
• The new spines included mature, mushroom-shaped morphologies (indicative of functional synapses) as well as thin/filopodial spines (indicative of developing connections)
• Spine density improvements correlated with cognitive performance improvements in the same animals, supporting a causal link between structural connectivity and functional cognition

Dementia Model Studies

Dihexa has been tested in pharmacological models of cognitive impairment (scopolamine, amyloid-? injection) with consistent positive results. However, it has not been extensively tested in transgenic Alzheimer’s disease models (APP/PS1, 5xFAD, or similar), which more closely recapitulate the complex pathology of human AD. This is a significant gap in the preclinical evidence base.

The “10 Million Times More Potent Than BDNF” Claim: Context and Caveats

The “10 million times more potent than BDNF” comparison is the most widely cited statistic about Dihexa, and it is both technically defensible and deeply misleading when taken out of context. Understanding the caveats is essential for any serious evaluation of the compound.

What the Comparison Actually Measured

The 10? potency comparison was derived from a single in vitro assay: dendritic spine formation (spinogenesis) in cultured hippocampal neurons. Dihexa at picomolar concentrations induced equivalent spine formation to BDNF at nanomolar-to-micromolar concentrations. This is a legitimate finding that reflects Dihexa’s extraordinary ability to promote structural synaptic changes.

Why the Comparison Is Misleading

1. Different mechanisms, different pathways: BDNF acts through TrkB receptors. Dihexa acts through HGF/c-Met potentiation. They are not competing at the same receptor or in the same signaling cascade. Comparing their potency is like comparing the potency of aspirin (COX inhibitor) vs morphine (opioid agonist) for pain — the comparison is numerically possible but mechanistically meaningless.

2. Single endpoint: The comparison was limited to dendritic spine formation. BDNF has vast biological effects beyond spinogenesis — it regulates neuronal survival, synaptic plasticity, LTP, neurotransmitter release, gene expression, and mood. Dihexa has not been shown to replicate all of BDNF’s functions.

3. In vitro vs in vivo: Concentration-response relationships in neuronal culture do not translate directly to in vivo potency. The pharmacokinetics (absorption, distribution, metabolism, BBB penetration) and local concentration at the target site in a living brain are entirely different from a culture dish.

4. Potentiator vs agonist: Dihexa is a potentiator of existing HGF signaling, not a direct agonist. Its effective concentration depends on local HGF availability, which varies by brain region and physiological state. BDNF is a direct agonist that provides its own signal. This fundamental pharmacological distinction makes concentration-based potency comparisons problematic.

The Honest Assessment

Dihexa is a genuinely potent promoter of synaptogenesis with a unique mechanism of action. The 10? BDNF comparison, while technically derived from real data, obscures more than it reveals. A more accurate characterization: Dihexa is a picomolar-active HGF/c-Met potentiator that promotes structural synaptic connectivity through a mechanism distinct from and complementary to BDNF/TrkB signaling.

Blood-Brain Barrier Penetration and Oral Bioavailability

One of Dihexa’s most practically significant properties is its ability to cross the blood-brain barrier after systemic (including oral) administration — unusual for a peptide-derived compound.

BBB Transit Mechanisms

Dihexa’s BBB penetration is attributed to its lipophilic hexanoic acid modifications, which increase the molecule’s lipophilicity (LogP) sufficiently for passive transcellular diffusion across brain capillary endothelial cells. At 487 Da and with its modified lipophilic groups, Dihexa falls within the physicochemical space that permits passive BBB transit — similar to many CNS-active small molecules.

Oral Activity

McCoy et al. (2013) demonstrated that oral Dihexa (at doses of approximately 1-2 mg/kg in rats) produced cognitive improvements comparable to subcutaneous administration. Oral activity implies not only BBB penetration but also adequate oral bioavailability — resistance to gastric acid degradation, intestinal absorption, and first-pass hepatic metabolism. The hexanoic acid modifications that protect against peptidase degradation likely also confer resistance to gastric and intestinal proteases.

Quantitative oral bioavailability data (absolute %F) has not been published, so the efficiency of oral absorption remains uncertain. The fact that cognitive effects were observed with oral dosing confirms functional brain exposure but does not establish the fraction of the oral dose that reaches the brain.

Safety Concerns: The HGF/c-Met Cancer Question

The single most important safety concern with Dihexa — and the likely reason it has not advanced to clinical development — is the HGF/c-Met pathway’s well-established role in cancer.

c-Met in Oncology

c-Met is one of the most studied oncogenes in cancer biology. Activating mutations, amplification, or overexpression of c-Met drives tumor growth, invasion, and metastasis in multiple cancer types — including non-small cell lung cancer, hepatocellular carcinoma, gastric cancer, renal cell carcinoma, and glioblastoma. The pharmaceutical industry has invested billions in developing c-Met inhibitors (capmatinib, tepotinib, savolitinib, crizotinib) as cancer therapeutics, several of which are now FDA-approved (Comoglio et al., 2018, Nature Reviews Drug Discovery).

This creates an obvious paradox: Dihexa potentiates HGF/c-Met signaling, while the oncology field is developing drugs to inhibit the same pathway. If potentiating c-Met signaling promotes synaptic growth, could it also promote tumor growth?

The Counterarguments

Several factors potentially mitigate the cancer concern:

1. Potentiator vs constitutive activator: Dihexa potentiates HGF-dependent c-Met activation — it amplifies a normal, regulated signal. Cancer-driving c-Met mutations typically cause ligand-independent, constitutive activation. The biology of amplifying a normal signal is fundamentally different from creating an always-on oncogenic signal.

2. Picomolar doses: Dihexa is active at picomolar concentrations, meaning very small systemic exposure is needed. The local tissue concentrations achieved at effective doses may be orders of magnitude below those needed to influence tumor biology.

3. Intermittent dosing: Cognitive benefits appear to persist after treatment discontinuation (due to structural synapse formation), suggesting that chronic continuous exposure is not necessary. Brief treatment courses would limit cumulative c-Met pathway exposure.

4. Preclinical safety: Published animal studies have not reported tumor formation in Dihexa-treated animals, though these studies were short-term (weeks) and not designed as carcinogenicity assessments. Long-term carcinogenicity studies have not been performed.

The Honest Risk Assessment

The cancer concern with Dihexa is theoretical but pharmacologically legitimate. No one has demonstrated that Dihexa promotes tumor growth in any model system, but no one has rigorously tested the question either. The absence of evidence is not evidence of absence. For a compound that has never undergone formal toxicology or long-term safety assessment, the HGF/c-Met oncology connection represents a real and unresolved safety question that anyone involved in Dihexa research should take seriously.

Cognitive Peptide Landscape: Dihexa vs Selank vs Semax vs P21

Dihexa exists within a broader landscape of cognitive-active peptides, each with distinct mechanisms and evidence bases.

The cognitive peptide field is characterized by a tension between mechanistic novelty (Dihexa, P21) and clinical validation (Selank, Semax). For researchers prioritizing established evidence, Selank and Semax have the strongest clinical records (albeit primarily from Russian regulatory systems with different evidentiary standards than FDA/EMA). For researchers interested in the most mechanistically novel approach to synaptic structural repair, Dihexa remains uniquely positioned — but carries commensurately greater uncertainty. See our in-depth review of Selank research for detailed analysis of the GABAergic peptide approach.

Relevance to Neurodegenerative Disease Research

Alzheimer’s Disease

Alzheimer’s disease is characterized by progressive synaptic loss — synapse density in the hippocampus and cortex declines by 25-35% in mild cognitive impairment (MCI) and by 40-55% in moderate AD. This synaptic loss correlates more strongly with cognitive decline than amyloid plaque burden or neurofibrillary tangle density, leading many researchers to conclude that synapse loss is the primary structural correlate of AD cognitive symptoms (Selkoe, 2002, Science).

Dihexa’s ability to promote new synapse formation (synaptogenesis) in aged and amyloid-exposed neurons makes it mechanistically relevant to AD. If new synaptic connections can be established to replace those lost to disease, cognitive function might be partially restored even in the presence of ongoing amyloid and tau pathology. This “synaptic replacement” concept is distinct from anti-amyloid (remove the pathology) or anti-tau (prevent the spread) strategies — it addresses the functional consequence (synapse loss) rather than the underlying cause.

However, Dihexa has not been tested in the transgenic mouse models that best replicate AD pathology. Whether HGF/c-Met-driven synaptogenesis can outpace ongoing synaptic destruction in an active disease environment remains unknown.

Traumatic Brain Injury (TBI)

TBI damages synaptic connections through acute mechanical disruption (diffuse axonal injury) and chronic neuroinflammation. The HGF/c-Met pathway is naturally activated during neural repair following injury, and HGF levels increase in CSF after TBI. Dihexa’s potentiation of this endogenous repair signal could theoretically accelerate post-TBI synaptic recovery. Animal models of TBI have not been published with Dihexa, but the mechanistic rationale is strong.

Age-Related Cognitive Decline

Normal aging involves a 20-30% decline in hippocampal synaptic density without the pathology of AD. This “normal” synaptic loss underlies the memory complaints that most people experience after age 60. Dihexa’s demonstrated efficacy in aged (non-demented) rats for improving spatial memory and increasing dendritic spine density is directly relevant to this population — potentially the most appropriate and safest application given the absence of active disease pathology that could confound treatment effects.

Practical Research Considerations

Compound Stability

Dihexa is relatively stable compared to natural peptides. Its hexanoic acid modifications protect against enzymatic degradation, and the compound is stable in aqueous solution at physiological pH for extended periods when stored properly (lyophilized at -20°C or below). In solution, stability is best maintained at pH 4-6 with protection from light and heat.

Dosing in Published Research

Published animal studies have used Dihexa at approximately 0.5-2 mg/kg administered subcutaneously or orally in rats, with treatment durations of 2-4 weeks. The compound is typically dissolved in saline (subcutaneous) or delivered in drinking water or gavage (oral). These doses achieved cognitive improvements and measurable changes in dendritic spine density without reported adverse effects in the published literature.

Analytical Verification

As with all research peptides, analytical verification of compound identity and purity is essential. HPLC and mass spectrometry confirmation of the expected molecular weight (487.6 Da) and peptide sequence should be performed on any research-grade Dihexa before use in experiments.

Future Directions and Unanswered Questions

Critical Unknowns

• Human pharmacokinetics: No human PK data exists. Brain exposure, oral bioavailability, and metabolic clearance in humans are completely unknown.
• Long-term safety: No carcinogenicity, reproductive toxicity, or chronic toxicity studies have been published.
• Dose-response in humans: The picomolar in vitro potency does not directly predict the oral dose needed for human cognitive effects.
• Combinability: Whether Dihexa can be safely combined with other cognitive compounds, and whether combinatorial approaches produce additive or synergistic effects, has not been studied.
• Duration of effect: How long do Dihexa-induced synaptic changes persist? Weeks? Months? Permanently? The answer has profound implications for dosing frequency.

The HGF/c-Met Pathway as a Therapeutic Target

Regardless of Dihexa’s specific future, the HGF/c-Met pathway is now firmly established as a target for cognitive and neurodegenerative disease research. Athira Pharma’s fosgonimeton (despite its clinical disappointments) validated corporate investment in the pathway. Academic groups worldwide are developing HGF mimetics, c-Met modulators, and related compounds for neurological applications. Even if Dihexa never enters clinical development, the biological insights generated by Harding and Wright’s work have opened a productive field of investigation.

Next-Generation Approaches

Future compounds targeting the HGF/c-Met pathway for cognition will need to address the cancer safety question head-on. Approaches may include:

• Brain-restricted HGF/c-Met modulators (unable to potentiate c-Met in peripheral tissues where cancer risk is relevant)
• Biased c-Met modulators that activate synaptic growth signaling (PI3K/AKT) without activating invasion/migration signaling (Ras/ERK)
• Very short-course treatment protocols (days rather than weeks) that create lasting structural changes with minimal cumulative pathway exposure
• Combination approaches using Dihexa with c-Met inhibitors in non-CNS tissues to limit peripheral effects

Frequently Asked Questions

References

1. McCoy AT, Benoist CC, Wright JW, et al. Evaluation of metabolically stabilized angiotensin IV analogs as procognitive/antidementia agents. Journal of Pharmacology and Experimental Therapeutics. 2013;344(1):141-154. PubMed
2. Wright JW, Harding JW. Brain renin-angiotensin — a new look at an old system. Progress in Neurobiology. 2011;95(1):49-67. PubMed
3. Benoist CC, Wright JW, Zhu M, et al. Facilitation of hippocampal synaptogenesis and spatial memory by C-terminal truncated Nle1-angiotensin IV analogs. Journal of Pharmacology and Experimental Therapeutics. 2011;339(1):35-44. PubMed
4. Comoglio PM, Trusolino L, Boccaccio C. Known and novel roles of the MET oncogene in cancer: a coherent approach to targeted therapy. Nature Reviews Cancer. 2018;18(6):341-358. PubMed
5. Selkoe DJ. Alzheimer’s disease is a synaptic failure. Science. 2002;298(5594):789-791. PubMed
6. Wright JW, Kawas LH, Harding JW. A role for the brain RAS in Alzheimer’s and Parkinson’s diseases. Frontiers in Endocrinology. 2013;4:158. PubMed
7. Harding JW, Wright JW. Angiotensin IV-based peptides/small molecules as agents for enhancing synaptic connectivity. Neural Regeneration Research. 2014;9(11):1089-1091. PubMed
8. Kramar EA, Harding JW, Wright JW. Angiotensin II- and IV-induced changes in cerebral blood flow. Peptides. 1997;18(7):1073-1076. PubMed
9. Kawas LH, McCoy AT, Yamamoto BJ, et al. Development and characterization of a novel HGF activating peptide. Drug Design, Development and Therapy. 2013;7:1107-1115. PubMed

This article is for informational and educational purposes only. It does not constitute medical advice. The compounds discussed are for research purposes only and are not intended for human consumption. Always consult a qualified healthcare professional before making decisions about your health. Browse our catalog of research peptides.